ClinicalTrials.gg
Not yet recruitingNCT07862712ATLASUpdated Oct 15, 2026

Assessing Trauma-related Links Between Affective and Metabolic Systems

A Phase 4 interventional study of prazosin in Posttraumatic Stress Disorder, Metabolic Syndrome and Insulin Resistance, sponsored by VA Office of Research and Development. Not yet recruiting at 1 site in United States. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by VA Office of Research and Development · Phase 4, Interventional, and Treatment

How we know

Updated Oct 15, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
21 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies testing prazosin in Stress Disorders, Post-Traumatic — 1 open to participants now, 2 under way, 1 of them phase 3. Prazosin · Stress Disorders, Post-Traumatic.

Planned enrollment
8th of 21
70 · median 40
Started
2027
the only one that year
Phase 4
6 of 22
1 open now
Registered
22nd of 22
by date
Lead sponsor
3 of 22
VA Office of Research and Development

Among the 22 studies testing prazosin in Stress Disorders, Post-Traumatic, this one is the 8th largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2027, is one of 6 in phase 4, and was the 22nd registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

1 of the 22 studies testing prazosin in Stress Disorders, Post-Traumatic is open now, in 1 country.

By country, each count listing its studies:

Where they have run

About prazosin

Prazosin: first FDA approval 1976 (MINIPRESS). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 21 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing prazosin in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

KEY INFORMATION: The purpose of this study is to understand how insulin resistance (how your body processes sugar) and PTSD might be related. The goal is to improve the health of Veterans in three ways:

  1. Understanding health risks: The investigators want to learn why Veterans with post-traumatic stress disorder (PTSD) are more likely to develop medical problems related to insulin resistance, such as diabetes.
  2. Testing effects of a medication: The investigators are testing whether prazosin, a medication that studies have shown may address some PTSD symptoms, can also improve how the body responds to insulin. If it does, this could point to a specific biological pathway that could be targeted for development of new treatments to prevent insulin resistance and diabetes in Veterans with PTSD.
  3. Links to depression. The investigators will also look at whether insulin sensitivity affects depression symptoms in people with PTSD. This may inform future research into treatments for PTSD.
Read the detailed description

Background and Study Objective: Post-traumatic stress disorder (PTSD) affects as many as 15% of Veterans following deployment and is associated with high rates of medical comorbidities linked to insulin resistance (IR), which is present in over half of people with PTSD. PTSD severity is prospectively associated with increased risk of both worsening IR severity and new-onset type 2 diabetes mellitus, leading to premature mortality. Biological effects of trauma exposure are linked to downstream disruption of both brain and metabolic processes, with mounting evidence that trauma-related mechanisms leading to IR may be biologically distinct from that of IR in the general population. One potential mechanism linking trauma exposure to IR lies in studies of noradrenaline (NA) blockade, with 1 adrenoreceptor antagonists demonstrating benefit for insulin sensitivity in patients with IR and hypertension. While a substantial body of evidence supports a role for increased NA signaling in PTSD, the potential link between NA and IR in the context of PTSD deserves further investigation. This connection suggests that increased IR following trauma also has the potential to play a causal role in the generation of psychiatric symptoms, particularly depressive symptoms, with multiple studies suggesting a potential causal relationship of IR on depressive symptoms. Defining mechanistic links between mental health and metabolic disorders have important clinical implications that may improve our approach to treating both mental and physical health disorders in Veterans with a history of trauma.

Study Design and Methods: Interrelationships among NA signaling (estimated by standing systolic blood pressure), insulin sensitivity (estimated by Oral Glucose Insulin Sensitivity index), and mental health symptoms will be examined in a population of Veterans with current PTSD. The effect of prazosin-mediated 1 adrenoreceptor antagonism on insulin sensitivity will be assessed in an open label single-arm interventional clinical trial design, with exploratory analysis of a potential mediating effect of improved insulin sensitivity on improvement in depression. These measures will be used to test the hypotheses pertaining to Veterans with PTSD: (1) increased NA signaling and hyperarousal symptoms are associated with lowered insulin sensitivity, (2) lowered insulin sensitivity is associated with elevated depression symptoms, (3) insulin sensitivity will improve with prazosin-mediated 1 antagonism, and (4) improvement in insulin sensitivity will be associated with improvement in depressive symptoms in response to prazosin.

This work is expected to contribute to Veteran's health in three major ways: (1) The investigators are investigating biological mechanisms in Veterans with insulin resistance and PTSD. If this is successful, it will contribute to our understanding of why Veterans with PTSD are at increased risk for comorbid medical conditions related to insulin resistance such as diabetes. (2) The investigators are testing whether noradrenergic blockade with the medication prazosin, currently used to treat PTSD, affects insulin sensitivity in Veterans with PTSD. If successful, this would identify a specific biological pathway that could be targeted for development of novel pharmacotherapeutic approaches to insulin resistance and downstream diabetes in Veterans with PTSD. (3) Our results may also provide information about the effect of insulin sensitivity on depressive symptoms in PTSD. This information has potential to contribute to the development of new strategies for treating, or even preventing, depression in PTSD, as well as overall PTSD treatment strategies.

03

Conditions studied

  • Posttraumatic Stress Disorder
  • Metabolic Syndrome
  • Insulin Resistance

Keywords

  • Stress Disorders, Post-Traumatic
  • Metabolic Syndrome
  • Insulin Resistance
04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Veteran of the US military
  2. Diagnosis of post-traumatic stress disorder (PTSD) defined by (DSM-5) symptom count on Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)

Exclusion criteria

Exclusion Criteria:

  1. Any form of diabetes as defined by the American Diabetes Association. Exceptions may be made for participants with previously undiagnosed, early, asymptomatic Type 2 Diabetes Mellitus (T2DM) who meet American Diabetes Association criteria for diabetes during study screening who wish to be included
  2. Diagnosis of -defined bipolar I, schizophrenia spectrum or other psychotic disorders (by MINI)
  3. Diagnosis of dementia or related progressive neurocognitive disorder, based on clinical records
  4. Diagnosis of moderate or severe substance use disorder (except for caffeine and nicotine) during the preceding 3 months
  5. Current use or use within the past 2 weeks of a medication with significant 1-AR or 2-AR activity (prazosin, doxazosin, alfuzosin, clonidine, guanfacine), or opiates
  6. Current use or use within the past 3 months of antipsychotics, medications, or glucose-lowering medications, including but not limited to metformin and GLP-1 agonists
  7. to prazosin
  8. History of moderate or severe Traumatic Brain Injury (TBI) as defined by the Ohio State University TBI Identification Method
  9. Increased risk of suicide that necessitates inpatient treatment, intensive outpatient care, or treatment excluded by the protocol
  10. Pregnancy or lactation, or anticipated pregnancy at any point during study participation
  11. Ongoing or initiation of new treatment with evidence-based trauma-focused therapy for post-traumatic stress disorder (PTSD) within 2 weeks of baseline. Supportive psychotherapy may be continued during the study.
  12. Current enrollment in another interventional trial for post-traumatic stress disorder (PTSD)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Prazosin

    The investigators will collect mental health and metabolic measures before and after prazosin treatment

    Drug: prazosin

Interventions

  • All participants will receive prazosin for 12 weeks according to a titration schedule informed by our prior studies, up to a minimum of 1mg in the morning and 3mg at night, up to a total daily dose of 16mg as tolerated. Higher doses may be considered as clinically appropriate.

    Also known as: Minipress

06

What researchers measure

Primary outcomes

  1. Noradrenergic signaling and insulin sensitivity

    Correlation between baseline noradrenergic signaling (standing systolic blood pressure) and insulin sensitivity (OGIS)

    Time frame: 5 years

  2. Insulin sensitivity change after prazosin

    Change in insulin sensitivity (OGIS) in response to prazosin

    Time frame: 5 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Dec 2031, 57 months later.

Of 30 non-industry phase 4 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 71. This study's planned 57 months is close to that.

Counting every sponsor, half of 31 studies reached it within 52 months; a quarter within 36 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 7, 2026
StartEst.
Mar 1, 2027
Primary completionEst.
Dec 31, 2031
CompletionEst.
Dec 31, 2032
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
2 edited
What changed in the outcomes
  • ChangedBefore Aim 1 primary outcomeNow Noradrenergic signaling and insulin sensitivityTime frame: 5 years
  • ChangedBefore Aim 2 primary outcomeNow Insulin sensitivity change after prazosinTime frame: 5 years
Oct 15, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 2 updates
  1. Oct 15, 2026
    Primary outcomes 2 edited
    What changed in the outcomes
    • ChangedBefore Aim 1 primary outcomeNow Noradrenergic signaling and insulin sensitivityTime frame: 5 years
    • ChangedBefore Aim 2 primary outcomeNow Insulin sensitivity change after prazosinTime frame: 5 years
    + 3 other changes: identifiers, verification date and arm descriptions
  2. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07862712
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Mar 1, 2027 (estimated)
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Oct 15, 2026

Study contacts

Katharine J Liang, MD PhD
Contact
katharine.liang@va.gov
(206) 277-6538
Carolyn L Fort, BS
Contact
carolyn.fort@va.gov
(206) 768-5259
Katharine J Liang, MD PhD
principal investigator · VA Puget Sound Health Care System Seattle Division, Seattle, WA

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prazosin

Start the discussion